Alliancebernstein L.P. I Mab Call Options Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
40Shares Held
15.4MCall Options Held
10.2KPut Options Held
0-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$29.6 Million0.6% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$20.6 Million3.04% of portfolio
-
Ariose Capital Management LTD Central, Hong Kong, K31.7MShares$8.44 Million2.68% of portfolio
-
Candriam S.C.A.1.13MShares$5.61 Million0.02% of portfolio
-
Sg Americas Securities, LLC464KShares$2.3 Million0.01% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $411M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...